assessment and management of patient with eye and vision disorder

56
Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 58 Assessment and Management of Patients With Eye and Vision Disorders

Upload: kalinga-institute-of-medical-sciences

Post on 17-May-2015

3.543 views

Category:

Documents


5 download

DESCRIPTION

SHARE AND LIKE IT

TRANSCRIPT

Page 1: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Chapter 58

Assessment and Management of Patients With Eye and

Vision Disorders

Chapter 58

Assessment and Management of Patients With Eye and

Vision Disorders

Page 2: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

QuestionQuestion

Is the following statement True or False?

Strabismus is involuntary oscillation of the eyeball.

Page 3: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

AnswerAnswer

False

Nystagmus is involuntary oscillation of the eyeball. Strabismus is a condition in which there is deviation from perfect ocular alignment.

Page 4: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

External Structures of the EyeExternal Structures of the Eye

Page 5: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Extraocular MusclesExtraocular Muscles

Page 6: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Visual PathwaysVisual Pathways

Page 7: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Cross-Section of the EyeCross-Section of the Eye

Page 8: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Internal Structures of the EyeInternal Structures of the Eye

• Refer to fig. 58-4

Page 9: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Assessment and Evaluation of VisionAssessment and Evaluation of Vision

• Ocular history

• Visual acuity

– Snellen chart

• Record each eye

• 20/20 means the patient can read the “20” line at a distance of 20 feet

• Finger count or hand motion

Page 10: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Examination of the External StructuresExamination of the External Structures

• Note any evidence of irritation, inflammatory process, discharge, etc.

• Assess eyelids and sclera

• Assess pupils and pupillary response; use darkened room

• Note gaze and position of eyes

• Assess extraocular movements

• Ptosis: drooping eyelid

• Nystagmus: oscillating movement of eyeball

Page 11: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Diagnostic EvaluationDiagnostic Evaluation

• Ophthalmoscopy

– Direct and indirect

– Examines the cornea, lens and retina

• Slit-lamp examination

• Color vision testing

• Amsler grid

• Ultrasonography

• Fluorescein and indocyanine green angiography

Page 12: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Diagnostic EvaluationDiagnostic Evaluation

• Tonometry

– Measures intraocular pressure

• Gonioscopy

– Visualizes the angle of the anterior chamber

• Perimetry testing

– Evaluates field of vision

– Scotomas: blind areas in the visual field

Page 13: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Impaired VisionImpaired Vision

• Refractive errors

– Can be corrected by lenses which focus light rays on the retina

• Emmetropia: normal vision

• Myopia: nearsighted

• Hyperopia: farsighted

• Astigmatism: distortion due to irregularity of the cornea

Page 14: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Eyeball shape determines visual acuity in refractive errorsEyeball shape determines visual acuity in refractive errors

Page 15: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

GlaucomaGlaucoma

• A group of ocular conditions in which damage to the optic nerve is related to increased intraocular pressure (IOP) caused by congestion of the aqueous humor

• The leading cause of blindness in adults in the U.S.

• Incidence increases with age

• Risk factors

Page 16: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Pathophysiology of GlaucomaPathophysiology of Glaucoma

• Normal Outflow of Aqueous Humor

• Refer to fig. 58-7

• In glaucoma, aqueous production and drainage are not in balance.

• When aqueous outflow is blocked, pressure builds up in the eye.

• Increased IOP causes irreversible mechanical and/or ischemic damage.

Page 17: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Types of GlaucomaTypes of Glaucoma

• Open-angle

– Chronic open angle glaucoma

– Normal tension glaucoma

– Ocular hypertension

• Angle-closure (pupillary block) glaucoma

– Acute angle-closure

– Subacute angle-closure

– Chronic angle-closure

• Congenital glaucomas and glaucoma secondary to other conditions

Page 18: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Clinical ManifestationsClinical Manifestations

• “Silent thief”; unaware of the condition until there is significant vision loss; peripheral vision loss, blurring, halos, difficulty focusing, difficulty adjusting eyes to low lighting

• May also have aching or discomfort around eyes or headache

Page 19: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Diagnostic FindingsDiagnostic Findings

• Tonometry to assess IOP

• Gonioscopy to assess the angle of the anterior chamber

• Perimetry to assess vision loss

• Progression of visual field defects

• Refer to fig. 58.8

Page 20: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Treatment Treatment

• Goal is to prevent further optic nerve damage

• Maintain IOP within a range unlikely to cause damage

• Pharmacologic therapy

• Surgery

– Laser tribeculoplasty

– Laser iridotomy

– Filtering procedures

– Tribeculectomy

– Drainage implants or shunts

Page 21: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing ManagementNursing Management• Patient education.

• Focus on maintaining the therapeutic regimen for lifelong control of a chronic condition.

• Emphasize the need for adherence to therapy and continued care to prevent further vision loss.

• Provide education regarding use and effects of medications.

• Medications used for glaucoma may cause vision alterations and other side effects. The action and effects of medications need to be explained to promote compliance.

• Provide support and interventions to aid the patient in adjusting to vision loss/potential vision loss.

Page 22: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

CataractsCataracts

• An opacity or cloudiness of the lens

• Increased incidence with aging; by age 80 more than half of all Americans have cataracts

• A leading cause of disability in the U.S.

• Risk factors

Page 23: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

CataractCataract

Page 24: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Clinical ManifestationsClinical Manifestations

• Painless, blurry vision

• Sensitivity to glare

• Reduced visual acuity

• Other effects include myopic shift, astigmatism, diplopia (double vision), and color shifts including brunescens (color value shift to yellow-brown)

• Diagnostic findings include decreased visual acuity and opacity of the lens by ophthalmoscope, slit-lamp, or inspection

Page 25: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Surgical ManagementSurgical Management

• If reduced vision does not interfere with normal activities, surgery is not needed.

• Surgery is preformed on an outpatient basis with local anesthesia.

• Surgery usually takes less than 1 hour and patients are discharged soon afterward.

• Complications are rare but may be significant.

Page 26: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Types of Cataract SurgeryTypes of Cataract Surgery

• Intracapsular cataract extraction (ICCE): removes entire lens, rarely done today

• Extracapsular cataract extraction (ECCE): maintains the posterior capsule of the lens, reducing potential postoperative complications

• Phacoemuslification: an ECCE which uses an ultrasonic device to suction the lens out through a tube; incision is smaller than with standard ECCE

• Lens replacement: after removal of the lens by ICCE or ECCE, the surgeon inserts an intraocular lens implant (IOL). This eliminates the need for aphakic lenses, however, the patient may still require glasses.

Page 27: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing ManagementNursing Management

• Preoperative care

• Usual preoperative care for ambulatory surgery

• Dilating eye drops or other medications as ordered

• Postoperative care

• Patient teaching

• Provide written and verbal instructions

• Instruct patient to call physician immediately if vision changes; continuous flashing lights appear; redness, swelling, or pain increase; type and amount of drainage increases; or significant pain is not relieved by acetaminophen

Page 28: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Corneal DisordersCorneal Disorders• Treatment of diseased corneal tissue

– Phototherapeutic keratectomy

– Keratoplasty

– Use of donor tissue for transplant

– Need for follow-up and support

– Potential graft failure; teach signs and symptoms

• Refractive surgery

– Elective procedures to recontour corneal tissue and correct refractive errors

– Patient need counseling regarding potential benefits, risks, and complications.

Page 29: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

LASIKLASIK

• Refer to fig. 58-10

Page 30: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Retinal DisordersRetinal Disorders

• Retinal detachment

• Retinal vascular disorders

– Central retina vein occlusion

– Branch retinal vein collusion

– Central retinal vein occlusion

– Macular degeneration

Page 31: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Retinal DetachmentRetinal Detachment

• Separation of the sensory retina and the RPE (retinal pigment epithelium)

• Manifestations: sensation of a shade or curtain coming across the vision of one eye, bright flashing lights, sudden onset of floaters

• Diagnostic findings: assess visual acuity, assessment of retina by indirect ophthalmoscope, slit-lamp, stereo fundus photography, and fluorescein angiography. Tomography and ultrasound may also be used

Page 32: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Retinal DetachmentRetinal Detachment

Page 33: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Surgical TreatmentSurgical Treatment

• Scleral buckle

• Pars plana vitrectomy

– Removal of vitreous locating the incisions at the pars plana

– Frequently used in combination with other procedures

• Pneumatic retinoplexy

– Injected gas bubble, liquid, or oil is used is used to flatten the sensory retina against the RPE

– Postoperative positioning is critical

Page 34: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Scleral BuckleScleral Buckle

Page 35: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing ManagementNursing Management

• Patient teaching

– Eye surgery is most often done as an outpatient procedure so patient education is vital

– Signs and symptoms of complications, especially increased IOP and infection

• Promote comfort

• Patient may need to lie in a special position with pneumatic retinoplexy

Page 36: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Retinal Vein or Artery OcclusionRetinal Vein or Artery Occlusion

• Loss of vision can occur from retinal vein or artery occlusion

• Occlusions may result from atherosclerosis, cardiac valvular disease, venous stasis, hypertension, or increased blood viscosity; and associated risk factors are diabetes mellitus, glaucoma, and aging.

• Patient may report decreased visual acuity or sudden loss of vision

Page 37: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Macular DegenerationMacular Degeneration• Age-related macular degeneration (AMD)

• The most common cause of vision loss in persons older than age 60

• Types

– Dry or nonexudative type; most common, 85–90%

• Slow breakdown of the layers of the retinal with the appearance of drusen

– Wet type

• May have abrupt onset

• Proliferation of abnormal blood vessels growing under the retina—choroidal revascularization (CNV)

Page 38: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Vision Loss Associated with Macular DegenerationVision Loss Associated with Macular Degeneration

• Refer to fig. 58-15

Page 39: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Retina Showing Drusen and AMDRetina Showing Drusen and AMD

Page 40: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Progression of AMD: Pathways to Vision LossProgression of AMD: Pathways to Vision Loss

Page 41: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Photodynamic Therapy for Slowing Progression of AMDPhotodynamic Therapy for Slowing Progression of AMD

• Light-sensitive verteporfin dye is injected into vessels. A laser then activates the dye, shutting down the vessels without damaging the retina.

• The result is to slow or stabilize vision loss.

• Patient must avoid exposure to sunlight or bright light for 5 days after treatment to avoid activation of dye in vessels near the surface of the skin.

Page 42: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Nursing ManagementNursing Management

• Patient teaching

• Supportive care

• Promote safety

• Recommendations to improve lighting, magnification devices, and referral to vision center to improve/promote function

Page 43: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

TraumaTrauma

• Prevention of injury

• Patient and public education

• Emergency treatment

– Flush chemical injuries

– Do not remove foreign objects

– Protect using metal shield or paper cup

• Potential for sympathetic ophthalmia causing blindness in the uninjured eye with some injuries

Page 44: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Protective Eye PatchesProtective Eye Patches

Page 45: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Infectious and Inflammatory disordersInfectious and Inflammatory disorders

• Dry eye syndrome

• Conjunctivitis (“pink eye”)

– Classified by cause—bacterial, viral, fungal, parasitic, allergic, toxic

– Viral conjunctivitis is contagious

• Uveitis

• Orbital cellulitis

Page 46: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Hyperemia in Viral ConjunctivitisHyperemia in Viral Conjunctivitis

Page 47: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Ocular Consequences of Systemic DiseaseOcular Consequences of Systemic Disease

• Diabetic retinopathy

– Diabetes is a leading cause of blindness in people age 20–74

• Ophthalmic complications associated with AIDS

• Eye changes associated with hypertension

Page 48: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Ophthalmic MedicationsOphthalmic Medications

• Ability of the eye to absorb medication is limited.

• Barriers to absorption include the size of the conjunctival sac, corneal membrane barriers, blood-ocular barriers, and tearing, blinking, and drainage

• Intraocular injection or systemic medication may be needed to treat some eye structures or to provide high concentrations of medication.

• Topical medications (drops and ointments) are most frequently used because they are least invasive, have fewest side effects, and permit self administration.

Page 49: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Ophthalmic MedicationsOphthalmic Medications

• Topical anesthetics

• Mydriatics (dilate) and cycloplegics (paralyze)

– Contraindicated with narrow angles or shallow anterior chambers and inpatients on monoamine oxidase inhibitors or tricyclic antidepressant

– May cause CNS symptoms and increased BP especially in children or the elderly

• Anti-infective medications

– Antibiotic, antifungal, or antiviral products

Page 50: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Ophthalmic MedicationsOphthalmic Medications

• Medications used for glaucoma

– Increase aqueous outflow or decrease aqueous production

– May constrict the pupil and may affect ability to focus the lens of the eye; affects vision

– May also may produce systemic effects

• Anti-inflammatory drugs; corticosteroid suspensions

– Side effects of long-term topical steroids include glaucoma, cataracts, and increased risk of infection. To avoid these effects, oral NSAID therapy may be used as an alternate to steroid use

Page 51: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Low Vision and BlindnessLow Vision and Blindness• Low vision

– Visional impairment that requires devices and strategies in addition to corrective lenses

– Best corrected visual acuity (BCVA) of 20/70 to 20/200

• Blindness

– BCVA 20/400 to no light perception

– Legal blindness is BCVA that does not exceed 20/200 in better eye or widest filed of vision is 20 degrees or less

• Impaired vision often is accompanied by functional impairment

Page 52: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Assessment of Low VisionAssessment of Low Vision

• History

• Examination of distance and near visual acuity, visual field, contrast sensitivity, glare, color perception, and refraction

• Special charts may be used for low vision

• Nursing assessment must include assessment of functional ability, and coping and adaptation in emotional, physical, and social areas

Page 53: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

ManagementManagement

• Support coping strategies, grief processes and acceptance of visual loss

• Strategies for adaptation to the environment

– Placement of items in room

– “Clock method” for trays

• Communication strategies

• Collaboration with low-vision specialist, occupational therapy or other resources

• Braille or other methods for reading/communication

• Service animals

Page 54: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

Safety Measures and TeachingSafety Measures and Teaching

• Patient teaching is a vital nursing intervention for patient with eye and vision disorders

• Prevention of eye injuries; education

• Safety strategies for patients with low vision in the hospital and home setting

• Patient teaching after eye surgery or trauma

– Potential complications

– Loss of binocular vision with patch or vision impairment of one eye; safety

– Use of eye patch and shield

Page 55: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

QuestionQuestion

Which medication is administered for glaucoma, uveitis, or after surgery?

A.Atropine

B.Cyclopentolate

C.Phenylephrine

D.Tropicamide

Page 56: ASSESSMENT AND MANAGEMENT OF PATIENT WITH EYE AND VISION DISORDER

Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

AnswerAnswer

A

A.The medication that is administered for glaucoma, uveitis, or after surgery is atropine. Cyclopentolate, phenylephrine, and tropicamide are administered for pupillary dilation for opthalmoscopy and surgical procedures.